Soo Park

Learn how to spot and treat cemiplimab immune side effects early, and why multidisciplinary teams improve advanced cutaneous SCC outcomes.

Recurrent facial squamous cell cancer with CLL challenges surgery and radiation; experts weigh immunotherapy, cemiplimab data, and patient goals.

Dr. Park addresses management of low-grade immune-related adverse events (irAEs), the most common toxicities encountered with checkpoint inhibitors, including dermatitis, pruritus, and GI symptoms.

Dr. Zager outlines a monitoring strategy for the Case 1 patient who is NED following surgery and radiation.

Expert panel explains extremely high-risk cutaneous SCC after surgery and radiation, and why adjuvant cemiplimab may curb recurrence.

Real-world cemiplimab data and neoadjuvant results show strong responses in high-risk cutaneous SCC, guiding treatment for frail, complex patients.

C-POST shows adjuvant cemiplimab cuts recurrence risk in high‑risk cutaneous SCC after surgery and radiation, reshaping multidisciplinary care.

Learn red flags for advanced cutaneous SCC and how PD‑1/PD‑L1 immunotherapy offers durable responses, reshaping treatment beyond surgery.

Learn when high-risk skin SCC needs early oncology referrals, imaging, and coordinated tumor-board care to avoid delays and improve outcomes.

Learn how clinicians spot aggressive cutaneous squamous cell carcinoma and when multidisciplinary care and immunotherapy improve outcomes.